Bartlett & Co’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | $37K | Hold |
140
| – | – | ﹤0.01% | 752 |
|
|
2023
Q3 | $36K | Hold |
140
| – | – | ﹤0.01% | 715 |
|
|
2023
Q2 | $40K | Hold |
140
| – | – | ﹤0.01% | 710 |
|
|
2023
Q1 | $39K | Hold |
140
| – | – | ﹤0.01% | 604 |
|
|
2022
Q4 | $39K | Hold |
140
| – | – | ﹤0.01% | 610 |
|
|
2022
Q3 | $37K | Hold |
140
| – | – | ﹤0.01% | 611 |
|
|
2022
Q2 | $29K | Hold |
140
| – | – | ﹤0.01% | 667 |
|
|
2022
Q1 | $29K | Buy |
+140
| New | +$30.4K | ﹤0.01% | 671 |
|
|
2021
Q4 | – | Sell |
-140
| Closed | -$40K | – | 457 |
|
|
2021
Q3 | $40K | Sell |
140
-116
| -45% | -$38K | ﹤0.01% | 541 |
|
|
2021
Q2 | $89K | Hold |
256
| – | – | ﹤0.01% | 427 |
|
|
2021
Q1 | $72K | Buy |
256
+115
| +82% | +$31K | ﹤0.01% | 476 |
|
|
2020
Q4 | $35K | Sell |
141
-111
| -44% | -$28.6K | ﹤0.01% | 586 |
|
|
2020
Q3 | $71K | Hold |
252
| – | – | ﹤0.01% | 437 |
|
|
2020
Q2 | $67K | Hold |
252
| – | – | ﹤0.01% | 444 |
|
|
2020
Q1 | $80K | Buy |
+252
| New | +$76.5K | ﹤0.01% | 388 |
|
|
2019
Q3 | $59K | Buy |
252
+180
| +250% | +$41.9K | ﹤0.01% | 497 |
|
|
2019
Q2 | $17K | Buy |
72
+45
| +167% | +$10.4K | ﹤0.01% | 548 |
|
|
2019
Q1 | $6K | Buy |
27
+2
| +8% | +$630 | ﹤0.01% | 604 |
|
|
2018
Q4 | $8K | Hold |
25
| – | – | ﹤0.01% | 592 |
|
|
2018
Q3 | $9K | Hold |
25
| – | – | ﹤0.01% | 605 |
|
|
2018
Q2 | $7K | Sell |
25
-15
| -38% | -$4.22K | ﹤0.01% | 612 |
|
|
2018
Q1 | $11K | Buy |
40
+15
| +60% | +$4.66K | ﹤0.01% | 597 |
|
|
2017
Q4 | $8K | Hold |
25
| – | – | ﹤0.01% | 600 |
|
|
2017
Q3 | $8K | Hold |
25
| – | – | ﹤0.01% | 596 |
|
|
2017
Q2 | $7K | Sell |
25
-11
| -31% | -$2.91K | ﹤0.01% | 605 |
|
|
2017
Q1 | $10K | Hold |
36
| – | – | ﹤0.01% | 594 |
|
|
2016
Q4 | $10K | Hold |
36
| – | – | ﹤0.01% | 594 |
|
|
2016
Q3 | $11K | Sell |
36
-15
| -29% | -$4.44K | ﹤0.01% | 591 |
|
|
2016
Q2 | $12K | Buy |
51
+15
| +42% | +$3.95K | ﹤0.01% | 593 |
|
|
2016
Q1 | $9K | Hold |
36
| – | – | ﹤0.01% | 606 |
|
|
2015
Q4 | $11K | Hold |
36
| – | – | ﹤0.01% | 603 |
|
|
2015
Q3 | $11K | Hold |
36
| – | – | ﹤0.01% | 595 |
|
|
2015
Q2 | $15K | Buy |
36
+11
| +44% | +$4.42K | ﹤0.01% | 570 |
|
|
2015
Q1 | $11K | Buy |
+25
| New | +$9.85K | ﹤0.01% | 604 |
|
Other funds holding BIIB
Bartlett & Co's BIIB Position: Q4 2023 in Review
Bartlett & Co held its Biogen (BIIB) position steady in Q4 2023 at 140 shares worth $37K. The position accounts for ﹤0.01% of the portfolio, ranked #752.
Bartlett & Co first reported a position in BIIB in Q1 2015 and has held it in 34 quarters since. The position peaked at $89K in Q2 2021. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q4 2023.
- Bartlett & Co held 140 shares of Biogen worth $37K as of Q4 2023.
- Bartlett & Co left its Biogen share count unchanged in Q4 2023.
- Biogen made up ﹤0.01% of Bartlett & Co's portfolio in Q4 2023, its #752 holding.
- Bartlett & Co first reported a position in Biogen in Q1 2015 and has held it in 34 quarters since.
- Bartlett & Co's Biogen position peaked at $89K in Q2 2021.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q4 2023.
Based on Bartlett & Co's 13F filing for Q4 2023, filed 8 Jan 2024.